Search for a trial

Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)

This study has been transitioned to CTIS with ID 2023-507889-89-00 check the CTIS register for the current data. REMAP-CAP: The goal of the study is to investigate the best treatment regime for pneumonia patients. For non-pandemic pneumonia (…

PLASOMA Ultimate Safety and Efficacy Study

This study is designed to confirm the safety and efficacy of PLASOMA after CE marking:1. in a larger population,2. in a more diverse population, consisting also of non-diabetic wound types, and3. including long-term safety.and to determine the…

The effect of postoperative glucose control with a basal bolus versus a sliding scale insulin regimen on the incidence of surgical site infections in people with type 2 diabetes mellitus: A multicentre, matched-pair, cluster-randomised controlled trial

The aim is to reduce SSI in PWT2D by implementing a proactive basal-bolus insulin regimen, compared to a widely used reactive sliding scale regimen. It is hypothesised that a proactive basal-bolus insulin regimen targeting glucose levels of 3.9-10…

A Phase 2, Multi-Center, Randomized, Placebo-Controlled, Dose-Finding Study Evaluating Efficacy, Safety and Tolerability of Different Doses and Regimens of Allocetra-OTS for the Treatment of Organ Failure in Adult Sepsis Patients

To compare the safety and efficacy of different doses and regimens of Allocetra-OTS to that of Placebo in the treatment of organ failure in adult sepsis patients

Antibiotic prophylaxis for children with recurrent respiratory infections: towards evidence-based guidelines

Primary: To determine whether three months of prophylactic treatment with co-trimoxazole causes a reduction in the number of days a child experiences at least two RTI symptoms in children aged 6 months to <=10 years with recurrent RTIs, when…

Influencing Progression of Airway Disease in Primary Antibody Deficiency

This study has been transitioned to CTIS with ID 2024-513124-41-00 check the CTIS register for the current data. To show the protective value and to measure cost effectiveness of higher Ig dosing on progression of lung disease in PAD.